(Q38587547)

English

What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?

scientific article published on 15 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer? (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Guillaume Ploussard

9

object named as

Guillaume Ploussard

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

author name string

Souhil Lebdai

1

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Victor Basset

2

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Julien Branchereau

3

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Alexandre de La Taille

4

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Vincent Flamand

5

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Thierry Lebret

6

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Thibaut Murez

7

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Yann Neuzillet

8

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

François Audenet

10

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

publication date

15 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

World Journal of Urology

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

617-624

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1687-0

21 January 2018

Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26373956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00345-015-1687-0

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38587547&oldid=2201855735"